Vaxart, Inc.
For the period ended Jul 16, 2026. Filed Jul 17, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jul 16, 2026 · Filed Jul 17, 2026
Use the contents to explore the available documents and sections.
Contents
PROXY STATEMENT
proxy statement for the Annual Meeting (the “Proxy Statement”).
The following is a brief description of each matter voted upon and the results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter. Proxies for the Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended.
Proposal 1. Stockholders elected the six nominees for directors to serve until the Company’s 2027 annual meeting of stockholders or until their successors are duly elected and qualified. The voting results were as follows:
| Director Name | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| James B. Breitmeyer, M.D., Ph.D. | 86,985,391 | 13,060,491 | 10,585,218 |
| Kevin P. Finney | 80,409,424 | 19,636,458 | 10,585,218 |
| Elaine J. Heron, Ph.D. | 51,372,172 | 48,672,711 | 10,586,217 |
| Steven Lo | 50,272,817 | 49,772,065 | 10,586,218 |
| W. Mark Watson, C.P.A. | 77,497,037 | 22,548,845 | 10,585,218 |
| David Wheadon, M.D. | 51,931,124 | 48,113,758 | 10,586,218 |
Proposal 2. Stockholders ratified the selection by the
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.